Deruxtecan is an exatecan （Exa） derivative appended with a cleavable peptide linker.
It is a very potent inhibitor of topoisomerase I and an anticancer agent.
Deruxtecan is used to prepare antibody-drug conjugates （ADCs）, such as trastuzumab Deruxtecan （T-DXd, also known as Enhertu®, Daiichi Sankyo）, targeting HER2.
Deruxtecan is approved in HER2-expressing breast （BC） and gastric （GC） cancers.
This HRP-Deruxtecan conjugate is designed with similar linker chemistry as ADCs and PDCs prepared by our customer using our Antibody Deruxtecan Conjugation Kit （Cat#： CM11431） and our Protein Deruxtecan Conjugation Kit （Cat#： CM11432）.
This conjugate is synthesized at CellMosaic for our customer's use in horseradish peroxidase （HRP） based assays.
A long flexible PEG linker is also incorporated in the conjugate to retain HRP activity and Deruxtecan binding.
The final conjugate is HPLC-purified to obtain 1：1 Deruxtecan-labeled HRP and is lyophilized from PBS buffer containing sugar-based stabilizer for easy shipping and storage.The product is sold as 1 vial of 0.5 mg （Cat# CM53215-0.5MG） or 4 vials of 0.5 mg （Cat# CM53215-2MG）.
For bulk orders beyond this range, please contact us for a quote.
